<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Toxic conjunctivitis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Toxic conjunctivitis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Toxic conjunctivitis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Pedram Hamrah, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Deborah S Jacobs, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert A Wood, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jane Givens, MD, MSCE</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 04, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Toxic conjunctivitis (also called toxic keratoconjunctivitis) implies direct damage to ocular tissues from an offending agent, usually a preservative or medication. The toxic agent can cause a papillary or follicular response in the conjunctiva with chronic use, and the conjunctiva can become chemotic, edematous, and hyperemic. These features also occur in allergic conjunctivitis, with which toxic conjunctivitis is often confused.</p><p>The most common form of toxic conjunctivitis is ocular surface medicamentosa (OSM). OSM is a chemical toxicity and/or a delayed, cell-mediated hypersensitivity response of the ocular surface and adnexa to active drugs and/or preservatives. Topical preserved eye drops are increasingly used to treat glaucoma and ocular surface disorders, such as dry eye disease (DED). OSM is usually associated with protracted use of topical drops. If not diagnosed and treated in a timely manner, OSM can result in significant ocular surface symptoms and visual dysfunction, affecting quality of life, daily activities, and workplace productivity. Thus, proper diagnosis, differentiation from DED, and correct management are important.</p><p>Toxic conjunctivitis is reviewed here. The various forms of ocular allergy are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/5547.html" rel="external">"Allergic conjunctivitis: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/5549.html" rel="external">"Vernal keratoconjunctivitis"</a> and  <a class="medical medical_review" href="/z/d/html/5550.html" rel="external">"Atopic keratoconjunctivitis"</a> and  <a class="medical medical_review" href="/z/d/html/5553.html" rel="external">"Giant papillary conjunctivitis"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Toxic conjunctivitis may take days to years to develop but typically occurs with protracted use of topical ocular medications (usually longer than three months but can vary with the type of medication) [<a href="#rid1">1</a>]. There also appears to be a dose-response effect with regard to the preservative concentration and total amount of preservative-containing medications used [<a href="#rid2">2</a>]. Thus, toxic ocular reactions are most frequently reported in patients with glaucoma, who are on lifelong therapy with multiple medications [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H2822993878"><span class="h1">ETIOLOGY</span><span class="headingEndMark"> — </span>Certain topical medications and the preservatives in those medications, contact lens solutions, and <a class="drug drug_general" data-topicid="8660" href="/z/d/drug information/8660.html" rel="external">artificial tears</a> are the most common causes of toxic ocular reactions [<a href="#rid4">4</a>]. Cosmetics used on the eyelids are also implicated.</p><p>Topical eye medications are commercially available in two forms: single and multidose bottles or vials. Multidose bottles are convenient, cheap, and easy to use for patients, but they contain antimicrobial preservatives in order to prevent microorganism contamination and to ensure long-term stability as mandated by the US Food and Drug Administration (FDA) [<a href="#rid5">5</a>]. These preservatives can induce toxicity and hypersensitivity, resulting in ocular surface medicamentosa (OSM), particularly in patients who have chronic ocular disease, such as dry eye disease (DED) and glaucoma, in which multiple drops are used for long periods.</p><p>The most common commercially available preservatives used for topical eye drops are benzalkonium chloride (BAK or BAC), thimerosal, chlorobutanol, sodium perborate, stabilized oxychloro complex (SOC), polyquaternium-1, and an ionic buffer containing borate, <a class="drug drug_general" data-topicid="9940" href="/z/d/drug information/9940.html" rel="external">sorbitol</a>, propylene glycol, and zinc. They can cause toxic, irritant, or hypersensitivity reactions [<a href="#rid6">6</a>], although data from rabbit models suggest that the newer-generation SOC is less cytotoxic than the other preservatives [<a href="#rid1">1,3</a>]. In a randomized trial, patients who received newer-generation ionic buffer-preserved topical eye drops showed higher tear breakup time and lower superficial punctate keratopathy scores compared with those who received BAK-preserved drops [<a href="#rid7">7</a>].</p><p>BAK, a detergent, was first used as a preservative in hard contact lens solutions and has a broad range of antimicrobial activity. Since then, BAK has evolved as the most frequently used preservative in most classes of ophthalmic solutions, including antiglaucoma eye drops, due to its ability to break down corneal epithelial tight junctions and facilitate drug penetration [<a href="#rid8">8</a>]. It may damage the ocular surface, sensory nerves, and tear film. As a quaternary ammonium compound, BAK has been shown to cause apoptosis of corneal and conjunctival epithelial cells, subclinical inflammation of the conjunctival epithelium, loss of conjunctival goblet cells, conjunctival squamous metaplasia, and subepithelial fibrosis in both clinical and preclinical studies [<a href="#rid9">9</a>]. In one clinical study of BAK-containing drops, corneal permeability increased threefold in patients with DED compared with normal subjects [<a href="#rid10">10</a>].</p><p>Toxicity is especially common in the following topically applied eye medications [<a href="#rid11">11-17</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Aminoglycoside antibiotics, including <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a> and <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">tobramycin</a></p><p class="bulletIndent1"><span class="glyph">●</span>Antiviral agents, including trifluorothymidine (Viroptic) and idoxuridine (Herplex)</p><p class="bulletIndent1"><span class="glyph">●</span>Glaucoma medications, including <a class="drug drug_general" data-topicid="9163" href="/z/d/drug information/9163.html" rel="external">brimonidine</a> (Alphagan), <a class="drug drug_general" data-topicid="9997" href="/z/d/drug information/9997.html" rel="external">timolol</a> maleate (Timoptic), and <a class="drug drug_general" data-topicid="9772" href="/z/d/drug information/9772.html" rel="external">pilocarpine</a></p><p class="bulletIndent1"><span class="glyph">●</span>Topical anesthetics</p><p></p><p>Among the cosmetics, mascara, creams, and hair spray are commonly implicated in toxic reactions [<a href="#rid18">18,19</a>]. Typical cosmetics are known to contain &gt;100 chemical compounds, but the specific triggers in cosmetics are not known.</p><p class="headingAnchor" id="H3"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Preservatives commonly damage the corneal epithelium. Preexisting damage to the cornea due to dry eyes or other causes is a risk factor for toxic conjunctivitis but is not required for its development.</p><p>Results from a monkey model and human corneal epithelial cell culture suggest that preservatives in ophthalmic solutions are unlikely to cause significant direct toxicity to epithelium of normal cornea [<a href="#rid20">20</a>]. However, studies in rabbit models consistently demonstrate ocular surface toxicity with topical preservative-containing medications [<a href="#rid3">3,21</a>]. In one study, patients with dry eyes were at greater risk for the development of toxic papillary reactions than those without dry eyes [<a href="#rid22">22</a>].</p><p>A number of findings are seen in patients treated with preserved medications compared with those using preservative-free therapies:</p><p class="bulletIndent1"><span class="glyph">●</span>Decreased goblet cell density [<a href="#rid23">23</a>] and reduced tear film breakup time [<a href="#rid3">3</a>]. Disruption of the tear lipid layer by preservatives in multidose eye drops results in increased tear film evaporation, which subsequently leads to increased tear hyperosmolarity and ocular surface desiccation. Tear hyperosmolarity causes osmotic stress on the ocular surface epithelium.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Subclinical inflammation of conjunctival epithelium [<a href="#rid3">3</a>]. Biopsies show an increase in surface expression of inflammatory markers and mediators, including human leukocyte antigen (HLA)-DR, intercellular adhesion molecule 1 (ICAM-1), and chemokine (C-C motif) receptors CCR4 and CCR5 [<a href="#rid3">3,23,24</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Epithelial keratinization, squamous metaplasia, subconjunctival fibrosis, and increased apoptosis in the ocular epithelium [<a href="#rid3">3,24</a>].</p><p></p><p class="headingAnchor" id="H4"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Patients typically present with noticeable burning of the eyes. Conjunctival hyperemia, chemosis, mucus discharge, papillary reaction of the palpebral conjunctiva, and itching are common  (<a class="graphic graphic_picture graphicRef118350" href="/z/d/graphic/118350.html" rel="external">picture 1</a>). The eyelids can become swollen, thickened, and excoriated. Involvement is usually bilateral, unless the offending agent was used in only one eye.</p><p>In mild cases of toxic conjunctivitis, the cornea will show punctate epithelial staining with <a class="drug drug_general" data-topicid="8461" href="/z/d/drug information/8461.html" rel="external">fluorescein</a> dye application. In more severe cases, large epithelial erosions and corneal ulceration may develop. Degenerated epithelium can roll up and form pseudodendrites that are sometimes confused with herpetic dendrites.</p><p class="headingAnchor" id="H5"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis should be suspected in any patient with conjunctival injection who is using topical ocular products, particularly those containing preservatives.</p><p>The clinician should take account of all topical ocular medications that the patient is using and their duration of usage. The patient should be questioned about all systemic/topical medications and contact lens solutions used, with special attention to preservative-containing eye drops, their dosing, frequency, and duration of use. A common history is that the original eye condition improved upon initial treatment, but the eye symptoms worsened with continued use. A complete clinical evaluation of the ocular surface should be performed, which includes the Schirmer test, tear breakup time, corneal staining with <a class="drug drug_general" data-topicid="8461" href="/z/d/drug information/8461.html" rel="external">fluorescein</a> staining, and conjunctival staining with lissamine green. The diagnosis is typically confirmed when the eyedrops are discontinued and the clinical manifestations resolve. (See  <a class="medical medical_review" href="/z/d/html/5603.html" rel="external">"Diagnosis and classification of Sjögren’s disease", section on 'Tests for dry eye'</a>.)</p><p>Patch testing is rarely helpful for identification of the offending agent since toxic conjunctivitis is a local reaction. However, in vivo confocal microscopy is a promising diagnostic tool to assess and monitor the level of cellular inflammation and neurotoxicity in toxic conjunctivitis [<a href="#rid25">25-29</a>].</p><p class="headingAnchor" id="H6"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis includes the various forms of ocular allergy (seasonal and perennial allergic conjunctivitis [SAC and PAC], vernal and atopic keratoconjunctivitis [VKC and AKC], and giant papillary conjunctivitis [GPC]), hypersensitivity (allergic) reactions to ophthalmic medications, conjunctivitis medicamentosa, dry eye disease (DED), and early-stage ocular cicatricial pemphigoid (OCP). Toxic conjunctivitis can occur in addition to one of these conditions since most of these patients are treated with topical ophthalmic medications.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ocular allergy</strong> – The eyelids can become swollen, thickened, and excoriated in toxic conjunctivitis. By contrast, these eyelid findings are unusual in the various forms of ocular allergy (the exception being AKC). In addition, ocular allergy more commonly presents with itching. While itching can present in both, it is more common with allergy. Many times, the symptoms of toxic conjunctivitis coincide with the use of eyedrops. (See  <a class="medical medical_review" href="/z/d/html/5547.html" rel="external">"Allergic conjunctivitis: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/5549.html" rel="external">"Vernal keratoconjunctivitis"</a> and  <a class="medical medical_review" href="/z/d/html/5550.html" rel="external">"Atopic keratoconjunctivitis"</a> and  <a class="medical medical_review" href="/z/d/html/5553.html" rel="external">"Giant papillary conjunctivitis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypersensitivity reactions</strong> – Hypersensitivity reactions to topical ocular medications typically occur early in the course of treatment, whereas toxic reactions usually occur after prolonged use.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Conjunctivitis medicamentosa</strong> – Conjunctivitis medicamentosa is caused by overuse of vasoconstricting eyedrops [<a href="#rid30">30</a>]. It presents with increased conjunctival injection and rebound hyperemia that occurs when the medication is discontinued. It is thought to be similar to rhinitis medicamentosa that occurs with topical nasal decongestants. (See  <a class="medical medical_review" href="/z/d/html/7532.html" rel="external">"Chronic nonallergic rhinitis", section on 'Management of rhinitis medicamentosa'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dry eye disease</strong> – The signs and symptoms of DED can closely mimic those of toxic conjunctivitis. Differentiating the two conditions can be challenging because overuse of preserved <a class="drug drug_general" data-topicid="8660" href="/z/d/drug information/8660.html" rel="external">artificial tears</a> may result in the development of toxic conjunctivitis in underlying DED. Referral to a corneal specialist is recommended to try to determine whether the patient has DED, toxic conjunctivitis, or both. (See  <a class="medical medical_review" href="/z/d/html/6894.html" rel="external">"Dry eye disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ocular cicatricial pemphigoid</strong> – In its early phase, this disease may present only with signs of a chronic or relapsing conjunctivitis, with symptoms such as tearing, irritation, burning, or mucus drainage  (<a class="graphic graphic_picture graphicRef65724" href="/z/d/graphic/65724.html" rel="external">picture 2</a>). Eye involvement is usually unilateral initially. Extraocular involvement is seen in some patients. (See  <a class="medical medical_review" href="/z/d/html/15590.html" rel="external">"Ocular cicatricial pemphigoid"</a>.)</p><p></p><p class="headingAnchor" id="H7"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>Recognition of the diagnosis of toxic conjunctivitis and removal of the offending agent(s) are imperative to the success of treating this condition. Stopping as many topical medications as feasible is a good first step. The patient should be monitored closely by an ophthalmologist after the suspected agent is discontinued in case the actual cause was infectious.</p><p>A preservative-free preparation should be used if a specific medication is required and preservative toxicity is suspected. An oral medication may be offered in situations in which a topical medication is causing toxicity, if that option is available.</p><p>Cold compresses and preservative-free <a class="drug drug_general" data-topicid="8660" href="/z/d/drug information/8660.html" rel="external">artificial tears</a> or ointments may help with ocular irritation.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Topical corticosteroids</strong> – We use a short course (typically two to six weeks) of topical corticosteroid agents one to four times daily to aid in suppressing chronic ocular surface inflammation and alleviating symptoms in moderate to severe cases [<a href="#rid31">31</a>]. In mild cases, treatment one to two times a day is sufficient [<a href="#rid31">31</a>]. Topical corticosteroid treatment should be carried out only by an ophthalmologist.</p><p></p><p class="bulletIndent1">Treatment options include <a class="drug drug_general" data-topicid="10116" href="/z/d/drug information/10116.html" rel="external">loteprednol</a> etabonate 0.5% gel (0.003% benzalkonium chloride [BAK]), loteprednol 0.38% (0.003% BAK), loteprednol etabonate ointment (BAK-free), <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">prednisolone</a> <a class="drug drug_general" data-topicid="10269" href="/z/d/drug information/10269.html" rel="external">sodium phosphate</a> 0.5% (BAK-free), or other preservative-free topical corticosteroids.</p><p></p><p class="bulletIndent1">In cases of concurrent glaucoma and where toxicity is induced by glaucoma drops, <a class="drug drug_general" data-topicid="10116" href="/z/d/drug information/10116.html" rel="external">loteprednol</a> etabonate drops or gel are preferred as they carry a lower risk for increased intraocular pressure. Further, in these cases, loteprednol etabonate 0.5% gel or 0.38% are preferred over loteprednol etabonate suspension (0.01% BAK), which has a higher concentration of BAK.</p><p></p><p class="bulletIndent1">All patients should have intraocular pressure monitored during treatment as topical corticosteroids can increase intraocular pressure. This is particularly true in patients with a personal or family history of glaucoma or intraocular hypertension.</p><p></p><p>Non-benzalkonium chloride (BAK)-containing formulations of topical medications are increasingly available, and use of these formulations may prevent many cases of toxic conjunctivitis. Further development of preservative-free or novel preservative preparations for ocular surface disease therapy may provide a promising approach in the prevention of ocular surface disease.</p><p class="headingAnchor" id="H8"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition – </strong>Toxic conjunctivitis implies direct damage to ocular tissues from a topically applied agent, either a medication or its preservative. Its clinical manifestations resemble those caused by allergens; therefore, it is frequently confused with allergic ocular disease. (See <a class="local">'Introduction'</a> above and <a class="local">'Etiology'</a> above and <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology – </strong>Toxic conjunctivitis most commonly occurs in patients on long-term therapy with multiple preservative-containing topical ocular medications, such as those used to treat glaucoma. (See <a class="local">'Epidemiology'</a> above and <a class="local">'Etiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations – </strong>Conjunctival hyperemia is the most common manifestation  (<a class="graphic graphic_picture graphicRef118350" href="/z/d/graphic/118350.html" rel="external">picture 1</a>). The eyelids may swell and the corneal epithelium become eroded. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis – </strong>A common history is that the original eye condition improved upon initial treatment but that the eye symptoms worsened with continued use of the offending agent. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis – </strong>The differential diagnosis includes the various forms of ocular allergy, hypersensitivity reactions to ophthalmic medications, conjunctivitis medicamentosa, dry eye disease (DED), and early-stage ocular cicatricial pemphigoid (OCP). (See <a class="local">'Differential diagnosis'</a> above and  <a class="medical medical_review" href="/z/d/html/5547.html" rel="external">"Allergic conjunctivitis: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/5549.html" rel="external">"Vernal keratoconjunctivitis"</a> and  <a class="medical medical_review" href="/z/d/html/5550.html" rel="external">"Atopic keratoconjunctivitis"</a> and  <a class="medical medical_review" href="/z/d/html/5553.html" rel="external">"Giant papillary conjunctivitis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management - </strong>Treatment involves discontinuing the suspected offending agent(s) and switching to preservative-free topical therapies or oral medications. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="headingAnchor" id="H1864158754"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Reza Dana, MD, MPH, MSc, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Noecker R. Effects of common ophthalmic preservatives on ocular health. Adv Ther 2001; 18:205.</a></li><li><a class="nounderline abstract_t">Jaenen N, Baudouin C, Pouliquen P, et al. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol 2007; 17:341.</a></li><li><a class="nounderline abstract_t">Baudouin C. Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma. Acta Ophthalmol 2008; 86:716.</a></li><li><a class="nounderline abstract_t">Li J, Tripathi RC, Tripathi BJ. Drug-induced ocular disorders. Drug Saf 2008; 31:127.</a></li><li><a class="nounderline abstract_t">Freeman PD, Kahook MY. Preservatives in topical ophthalmic medications: Historical and clinical perspectives. Expert Rev Ophthalmol 2009; 4:59.</a></li><li><a class="nounderline abstract_t">Hong J, Bielory L. Allergy to ophthalmic preservatives. Curr Opin Allergy Clin Immunol 2009; 9:447.</a></li><li><a class="nounderline abstract_t">Aihara M, Oshima H, Araie M, EXTraKT study group. Effects of SofZia-preserved travoprost and benzalkonium chloride-preserved latanoprost on the ocular surface -- a multicentre randomized single-masked study. Acta Ophthalmol 2013; 91:e7.</a></li><li><a class="nounderline abstract_t">Anwar Z, Wellik SR, Galor A. Glaucoma therapy and ocular surface disease: current literature and recommendations. Curr Opin Ophthalmol 2013; 24:136.</a></li><li><a class="nounderline abstract_t">Baudouin C, Pisella PJ, Fillacier K, et al. Ocular surface inflammatory changes induced by topical antiglaucoma drugs: human and animal studies. Ophthalmology 1999; 106:556.</a></li><li><a class="nounderline abstract_t">Göbbels M, Spitznas M. Influence of artificial tears on corneal epithelium in dry-eye syndrome. Graefes Arch Clin Exp Ophthalmol 1989; 227:139.</a></li><li><a class="nounderline abstract_t">FEDUKOWICZ H, WISE GN, ZARET MM. Toxic conjunctivitis due to antibiotics. Am J Ophthalmol 1955; 40:849.</a></li><li><a class="nounderline abstract_t">Benjamin KW. Toxicity of ocular medications. Int Ophthalmol Clin 1979; 19:199.</a></li><li><a class="nounderline abstract_t">Chen HT, Chen KH, Hsu WM. Toxic keratopathy associated with abuse of low-dose anesthetic: a case report. Cornea 2004; 23:527.</a></li><li><a class="nounderline abstract_t">Imperia PS, Lazarus HM, Dunkel EC, et al. An in vitro study of ophthalmic antiviral agent toxicity on rabbit corneal epithelium. Antiviral Res 1988; 9:263.</a></li><li><a class="nounderline abstract_t">Noecker RJ, Herrygers LA, Anwaruddin R. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea 2004; 23:490.</a></li><li><a class="nounderline abstract_t">Pisella PJ, Fillacier K, Elena PP, et al. Comparison of the effects of preserved and unpreserved formulations of timolol on the ocular surface of albino rabbits. Ophthalmic Res 2000; 32:3.</a></li><li><a class="nounderline abstract_t">Coles WH. Pilocarpine toxicity. Effects on the rabbit corneal endothelium. Arch Ophthalmol 1975; 93:36.</a></li><li><a class="nounderline abstract_t">Ciolino JB, Mills DM, Meyer DR. Ocular manifestations of long-term mascara use. Ophthal Plast Reconstr Surg 2009; 25:339.</a></li><li><a class="nounderline abstract_t">Sánchez Palacios A, Shaman F, Garcá JA, Sánchez Palacios MA. [Prevalence of cosmetic sensitivity among beauticians]. Allergol Immunopathol (Madr) 1995; 23:148.</a></li><li><a class="nounderline abstract_t">Khoh-Reiter S, Jessen BA. Evaluation of the cytotoxic effects of ophthalmic solutions containing benzalkonium chloride on corneal epithelium using an organotypic 3-D model. BMC Ophthalmol 2009; 9:5.</a></li><li><a class="nounderline abstract_t">Liang H, Baudouin C, Pauly A, Brignole-Baudouin F. Conjunctival and corneal reactions in rabbits following short- and repeated exposure to preservative-free tafluprost, commercially available latanoprost and 0.02% benzalkonium chloride. Br J Ophthalmol 2008; 92:1275.</a></li><li><a class="nounderline abstract_t">Wilson FM 2nd. Adverse external ocular effects of topical ophthalmic therapy: an epidemiologic, laboratory, and clinical study. Trans Am Ophthalmol Soc 1983; 81:854.</a></li><li><a class="nounderline abstract_t">Pisella PJ, Lala E, Parier V, et al. [Effect of preservatives on the conjunctiva: a comparative study of beta-blocker eye drops with and without preservatives in glaucoma patients]. J Fr Ophtalmol 2003; 26:675.</a></li><li><a class="nounderline abstract_t">Baudouin C. Allergic reaction to topical eyedrops. Curr Opin Allergy Clin Immunol 2005; 5:459.</a></li><li><a class="nounderline abstract_t">Villani E, Baudouin C, Efron N, et al. In vivo confocal microscopy of the ocular surface: from bench to bedside. Curr Eye Res 2014; 39:213.</a></li><li><a class="nounderline abstract_t">Hamrah P, Seyed-Razavi Y, Yamaguchi T. Translational Immunoimaging and Neuroimaging Demonstrate Corneal Neuroimmune Crosstalk. Cornea 2016; 35 Suppl 1:S20.</a></li><li><a class="nounderline abstract_t">Mastropasqua L, Agnifili L, Mastropasqua R, et al. In vivo laser scanning confocal microscopy of the ocular surface in glaucoma. Microsc Microanal 2014; 20:879.</a></li><li><a class="nounderline abstract_t">Sarkar J, Chaudhary S, Namavari A, et al. Corneal neurotoxicity due to topical benzalkonium chloride. Invest Ophthalmol Vis Sci 2012; 53:1792.</a></li><li><a class="nounderline abstract_t">Martone G, Frezzotti P, Tosi GM, et al. An in vivo confocal microscopy analysis of effects of topical antiglaucoma therapy with preservative on corneal innervation and morphology. Am J Ophthalmol 2009; 147:725.</a></li><li><a class="nounderline abstract_t">Spector SL, Raizman MB. Conjunctivitis medicamentosa. J Allergy Clin Immunol 1994; 94:134.</a></li><li class="breakAll">Hamrah P, Tufts University School of Medicine; Dana R, Harvard Medical School, 2018, personal communication.</li></ol></div><div id="topicVersionRevision">Topic 5555 Version 15.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11783457" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Effects of common ophthalmic preservatives on ocular health.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17534814" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Ocular symptoms and signs with preserved and preservative-free glaucoma medications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18537937" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18217789" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Drug-induced ocular disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Preservatives in topical ophthalmic medications: Historical and clinical perspectives</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19697451" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Allergy to ophthalmic preservatives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23241328" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Effects of SofZia-preserved travoprost and benzalkonium chloride-preserved latanoprost on the ocular surface -- a multicentre randomized single-masked study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23542350" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Glaucoma therapy and ocular surface disease: current literature and recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10080214" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Ocular surface inflammatory changes induced by topical antiglaucoma drugs: human and animal studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2721982" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Influence of artificial tears on corneal epithelium in dry-eye syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13268586" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Toxic conjunctivitis due to antibiotics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/376469" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Toxicity of ocular medications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15220742" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Toxic keratopathy associated with abuse of low-dose anesthetic: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3144240" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : An in vitro study of ophthalmic antiviral agent toxicity on rabbit corneal epithelium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15220734" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Corneal and conjunctival changes caused by commonly used glaucoma medications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10657748" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Comparison of the effects of preserved and unpreserved formulations of timolol on the ocular surface of albino rabbits.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1111486" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Pilocarpine toxicity. Effects on the rabbit corneal endothelium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19617808" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Ocular manifestations of long-term mascara use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8553988" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : [Prevalence of cosmetic sensitivity among beauticians].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19638217" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Evaluation of the cytotoxic effects of ophthalmic solutions containing benzalkonium chloride on corneal epithelium using an organotypic 3-D model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18723745" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Conjunctival and corneal reactions in rabbits following short- and repeated exposure to preservative-free tafluprost, commercially available latanoprost and 0.02% benzalkonium chloride.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6676985" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Adverse external ocular effects of topical ophthalmic therapy: an epidemiologic, laboratory, and clinical study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13130254" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : [Effect of preservatives on the conjunctiva: a comparative study of beta-blocker eye drops with and without preservatives in glaucoma patients].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16131924" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Allergic reaction to topical eyedrops.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24215436" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : In vivo confocal microscopy of the ocular surface: from bench to bedside.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27631352" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Translational Immunoimaging and Neuroimaging Demonstrate Corneal Neuroimmune Crosstalk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24576766" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : In vivo laser scanning confocal microscopy of the ocular surface in glaucoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22410563" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Corneal neurotoxicity due to topical benzalkonium chloride.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19181302" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : An in vivo confocal microscopy analysis of effects of topical antiglaucoma therapy with preservative on corneal innervation and morphology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8027493" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Conjunctivitis medicamentosa.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
